Literature DB >> 30560488

Venous thromboembolism in patients with cancer undergoing surgical exploration.

Samantha M Ruff1, Kathryn T Weber2, Adam Khader2, Charles Conte3, Alan Kadison3, James Sullivan3, John Wang3, Raza Zaidi3, Gary B Deutsch3.   

Abstract

Malignancy and surgery are both independent risk factors for venous thromboembolism (VTE) events. The current NCCN guidelines recommend VTE prophylaxis for up to 28 days after major abdominal or pelvic surgery for malignancy. We set out to evaluate the rate and timing of VTEs among patients with gastric, pancreatic, colorectal, and gynecologic malignancies who underwent surgery. We performed a retrospective review of the NSQIP database (2005-2013) focusing on patients with gastric, colorectal, pancreatic, and gynecologic malignancies. Our primary endpoint was a diagnosis of VTE within 30 days of surgery. We analyzed 128,864 patients in this study. On multivariable analysis, patients with pre-operative sepsis (OR 2.36, CI 2.04-2.76, p < 0.001), disseminated cancer (OR 1.73, CI 1.55-1.92, p < 0.001), congestive heart failure (OR 1.69, CI 1.25-2.28, p = 0.001), gastric cancer (OR 1.3, CI 1.09-1.56, p = 0.004), and pancreatic cancer (OR 1.2, CI 1.03-1.30, p = 0.021) were more likely to have a VTE. Of patients who had a VTE event, 34% occurred after discharge from surgery (gastric: 25%, colorectal 34%, pancreatic 31%, gynecologic malignancy 42%). Our study demonstrates that patients who undergo an operation for malignancy with pre-operative sepsis, disseminated cancer, congestive heart failure, gastric cancer, or pancreatic cancer are more likely to develop a VTE within 30 days of their operation. Of those patients who developed a VTE, approximately one-third occurred after discharge during a 30 day post-operative period. This data supports that further studies are needed to determine the appropriate length of post-operative VTE chemoprophylaxis in patients with cancer.

Entities:  

Keywords:  Cancer; Deep vein thrombosis; Discharge; Neoplasm; Surgery; Venous thromboembolism

Mesh:

Year:  2019        PMID: 30560488     DOI: 10.1007/s11239-018-1774-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  2 in total

1.  Extended duration chemoprophylaxis for venous thromboembolism following abdominopelvic oncologic surgery.

Authors:  John Kanitra; John Holtrop; Ali Jawad; Richard Berri
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

2.  Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study.

Authors:  Jin-Sung Yuk; Banghyun Lee; Kidong Kim; Myoung Hwan Kim; Yong-Soo Seo; Sung Ook Hwang; Yong Kyoon Cho; Yong Beom Kim
Journal:  BMC Cancer       Date:  2021-10-30       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.